Emerging sex differences in multiple aspects of this lethal brain cancer likely help explain the disease’s more favorable incidence and prognosis in females. And they may point to new targeted therapies.
A new study the Department of Cellular and Molecular Medicine identifies a never-before described survival pathway in cancer stem cells (CSCs) that may serve as a potential target for new triple-negative breast cancer (TNBC) treatment therapies.
Through a side-by-side comparison of CSC and non-CSC reactions in specific TLR cultures, Dr. Lathia and his teams found that CSCs in GB have adapted to express a lower level of the innate TLR4. These diminished TLR4 levels allow the CSCs to persist and multiply, repopulating a tumor in a hostile microenvironment.
Cleveland Clinic researchers solve a puzzle that brings them one step closer to finding a treatment for glioblastoma.